FRA:BAYN - Bayer Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
€55.66 -1.29 (-2.27 %)
(As of 05/20/2019 07:09 AM ET)
Previous Close€56.95
Today's Range€55.52 - €56.86
52-Week Range€91.58 - €123.82
Volume732,131 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, cosmetics, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, cold and cough, foot care, and sun protection categories. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The Animal Health segment develops and markets products and solutions for the prevention and treatment of disease in companion and farm animals to veterinarians. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University to jointly identify new drug targets for the treatment of pulmonary diseases, such as idiopathic pulmonary fibrosis. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Receive BAYN News and Ratings via Email

Sign-up to receive the latest news and ratings for BAYN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-214-301

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees111,015
Next Earnings DateN/A
OptionableNot Optionable

Bayer (FRA:BAYN) Frequently Asked Questions

What is Bayer's stock symbol?

Bayer trades on the FRA under the ticker symbol "BAYN."

What price target have analysts set for BAYN?

24 brokerages have issued 12-month price objectives for Bayer's shares. Their predictions range from €52.50 to €123.00. On average, they expect Bayer's stock price to reach €81.67 in the next year. This suggests a possible upside of 46.7% from the stock's current price. View Analyst Price Targets for Bayer.

What is the consensus analysts' recommendation for Bayer?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bayer in the last year. There are currently 1 sell rating, 11 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bayer.

Has Bayer been receiving favorable news coverage?

Media stories about BAYN stock have trended somewhat negative this week, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bayer earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave news articles about the healthcare company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of Bayer's key competitors?

What other stocks do shareholders of Bayer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bayer investors own include Hawkins (HWKN), CA (CA), BlackRock (BLK), Endologix (ELGX), The Coca-Cola (KO), ESSILOR INTL S/S (ESLOY), Basf (BAS), Chipotle Mexican Grill (CMG), Daimler (DAI) and Allianz (ALV).

Who are Bayer's key executives?

Bayer's management team includes the folowing people:
  • Mr. Werner Baumann, Chairman of Management & CEO (Age 57)
  • Mr. Wolfgang U. Nickl, CFO & Member of Management Board (Age 50)
  • Mr. Liam Condon, Pres of Bayer Crop Science Division & Member of Management Board (Age 51)
  • Dr. Kemal Malik, Head of Innovation & Member of Management Board (Age 57)
  • Dr. Hartmut Klusik, Head of HR, Technology & Sustainability, Labor Director and Member of Management Board (Age 63)

What is Bayer's stock price today?

One share of BAYN stock can currently be purchased for approximately €55.66.

What is Bayer's official website?

The official website for Bayer is https://www.bayer.de/.

How can I contact Bayer?

Bayer's mailing address is Kaiser-Wilhelm-Allee 1, LEVERKUSEN, 51373, Germany. The healthcare company can be reached via phone at +49-214-301.


MarketBeat Community Rating for Bayer (FRA BAYN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,378 (Vote Outperform)
Underperform Votes:  888 (Vote Underperform)
Total Votes:  2,266
MarketBeat's community ratings are surveys of what our community members think about Bayer and other stocks. Vote "Outperform" if you believe BAYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BAYN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel